S. 5244 · 119th Congress · Health

SUSTAIN 340B Act

In committee14k words Introduced Aug 5, 2026 · Latest action Aug 5, 2026

How far it has goneStage 2 of 6
  1. IntroducedAug 5, 2026 Done
  2. CommitteeReferred to Health, Education, Labor, and Pensions Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

9 organizations, more than 96% of Senate bills · 9 filings · Q3 2026

These 9 organizations’ PACs gave $43.5K to 6 of the 6 members sponsoring or cosponsoring S. 5244 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 1 of 1 quarter
    “…S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521…”

    $26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. American Hospital Association 1 of 1 quarter
    “…S. 5244, Supporting Underserved and Strengthening Transparency Accountability and Integrity Now (SUSTAIN) Act, all provisions; H.R. 3178 / S. 1600, The Save Healthcare Workers Act, all provisions; H.R. 929 / S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions; H.R. 1585…”

    $14.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Biotechnology Innovation Organization 1 of 1 quarter
    “…S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research…”

    $6.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing

6 more organizations, every filingPROUpgrade

Organizations that named S. 5244 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Aug 5, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Aug 5, 2026Introduced in Senate